Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance objectives at 6 months (in 94 patients) and 12 months (in 25 patients) REGENERA(TM) achieved high levels of patient and surgeon satisfaction Patients to be followed for up to five […]

Gold Production for YE 2025 and Award of Impact Benefit Agreement (“IBA”) GlobeNewswire January 08, 2026 Reykjavík, Jan. 08, 2026 (GLOBE NEWSWIRE) — Gold Production for YE 2025 of ~6.6koz1 above the mid-point of the annual 6-7koz guidance range And Award of Impact Benefit Agreement (“IBA”) TORONTO, ONTARIO – 8 January 2026 – Amaroq Ltd.

Eleva appoints Erich Rajkovic as new Chief Business Officer GlobeNewswire January 08, 2026 Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief Business Officer. Erich Rajkovic joined Eleva from Affimed, Mannheim/Germany, where he played

Shell fourth quarter 2025 update note GlobeNewswire January 08, 2026 The following is an update to the fourth quarter 2025 outlook and gives an overview of our current expectations for the fourth quarter. Outlooks presented may vary from the actual fourth quarter 2025 results and are subject to finalisation of those results, which are scheduled

Tensive reports positive pivotal trial top-line results showing REGENERA(TM) bioresorbable device may transform breast reconstruction GlobeNewswire January 08, 2026 Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance objectives at 6 months (in 94 patients) and 12 months (in

Just – Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the next three years HAMBURG, DE / ACCESS Newswire / January 8, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announces

FORT ATKINSON, Wis., Jan. 08, 2026 (GLOBE NEWSWIRE) — When should buyers or sellers choose a local real estate broker over a national or out-of-town option? That question is answered in a HelloNation article featuring Steve Mode of Wayne Hayes Real Estate in Fort Atkinson, WI. The piece offers insight into how decisions made during

ALBEMARLE, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — What matters most when bundling home and auto insurance? A HelloNation article explores how bundled insurance can do more than lower your premiums–it can improve how coverage works together across your household. The article, Bundled Home and Auto Coverage – What Really Matters, features insights from Kate

(Euronext Amsterdam:TOM2), LAS VEGAS, Jan. 08, 2026 (GLOBE NEWSWIRE) — TomTom (TOM2), the location technology specialist, today announced its continued collaboration with Microsoft to enhance its maps and navigation products. TomTom is enhancing its automotive navigation solutions, including the TomTom Automotive Navigation Application and TomTom AI Agent, through integration of Azure OpenAI in Microsoft Foundry

(Euronext Amsterdam:TOM2),(NASDAQ:VC), LAS VEGAS, Jan. 08, 2026 (GLOBE NEWSWIRE) — TomTom (TOM2), the location technology specialist, today announced the successful integration of its Automotive Navigation Application with the cognitoAI(TM) platform from Visteon, a global automotive technology leader in cockpit electronics. This collaboration delivers an onboard AI voice experience deeply integrated with an automotive navigation solution,